206 related articles for article (PubMed ID: 32244913)
1. Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Pocasap P; Weerapreeyakul N; Timonen J; Järvinen J; Leppänen J; Kärkkäinen J; Rautio J
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244913
[TBL] [Abstract][Full Text] [Related]
2. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
3. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
4. Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
Tomblin JK; Arthur S; Primerano DA; Chaudhry AR; Fan J; Denvir J; Salisbury TB
Biochem Pharmacol; 2016 Apr; 106():94-103. PubMed ID: 26944194
[TBL] [Abstract][Full Text] [Related]
5. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y
J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy.
Li L; Di X; Wu M; Sun Z; Zhong L; Wang Y; Fu Q; Kan Q; Sun J; He Z
Nanomedicine; 2017 Apr; 13(3):987-998. PubMed ID: 27890657
[TBL] [Abstract][Full Text] [Related]
8. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
10. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
Sato M; Harada-Shoji N; Toyohara T; Soga T; Itoh M; Miyashita M; Tada H; Amari M; Anzai N; Furumoto S; Abe T; Suzuki T; Ishida T; Sasano H
Sci Rep; 2021 Jan; 11(1):589. PubMed ID: 33436954
[No Abstract] [Full Text] [Related]
11. SAR study of tyrosine-chlorambucil hybrid regioisomers; synthesis and biological evaluation against breast cancer cell lines.
Descôteaux C; Brasseur K; Leblanc V; Parent S; Asselin E; Bérubé G
Amino Acids; 2012 Aug; 43(2):923-35. PubMed ID: 22102055
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
Patel M; Dalvi P; Gokulgandhi M; Kesh S; Kohli T; Pal D; Mitra AK
Int J Pharm; 2013 Feb; 443(1-2):245-53. PubMed ID: 23270998
[TBL] [Abstract][Full Text] [Related]
13. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
14. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
Huttunen KM; Gynther M; Huttunen J; Puris E; Spicer JA; Denny WA
J Med Chem; 2016 Jun; 59(12):5740-51. PubMed ID: 27253989
[TBL] [Abstract][Full Text] [Related]
15. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
16. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
Thiele NA; Kärkkäinen J; Sloan KB; Rautio J; Huttunen KM
Bioorg Med Chem Lett; 2018 Sep; 28(17):2856-2860. PubMed ID: 30055889
[TBL] [Abstract][Full Text] [Related]
17. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
18. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET).
Habermeier A; Graf J; Sandhöfer BF; Boissel JP; Roesch F; Closs EI
Amino Acids; 2015 Feb; 47(2):335-44. PubMed ID: 25385314
[TBL] [Abstract][Full Text] [Related]
19. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
Hayashi K; Jutabha P; Maeda S; Supak Y; Ouchi M; Endou H; Fujita T; Chida M; Anzai N
J Pharmacol Sci; 2016 Nov; 132(3):201-204. PubMed ID: 27567475
[TBL] [Abstract][Full Text] [Related]
20. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.
Kärkkäinen J; Laitinen T; Markowicz-Piasecka M; Montaser A; Lehtonen M; Rautio J; Gynther M; Poso A; Huttunen KM
Bioorg Chem; 2021 Jul; 112():104921. PubMed ID: 33933805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]